JP2023534916A - 視神経脊髄炎スペクトラム障害を治療する方法 - Google Patents

視神経脊髄炎スペクトラム障害を治療する方法 Download PDF

Info

Publication number
JP2023534916A
JP2023534916A JP2022581408A JP2022581408A JP2023534916A JP 2023534916 A JP2023534916 A JP 2023534916A JP 2022581408 A JP2022581408 A JP 2022581408A JP 2022581408 A JP2022581408 A JP 2022581408A JP 2023534916 A JP2023534916 A JP 2023534916A
Authority
JP
Japan
Prior art keywords
subject
nmosd
sgfap
need
seizures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022581408A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022006283A5 (enExample
Inventor
ウィリアム リース
エリエゼル カッツ
マイケル スミス
ナネット ミッテレダー
Original Assignee
ビエラ バイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビエラ バイオ インコーポレイテッド filed Critical ビエラ バイオ インコーポレイテッド
Publication of JP2023534916A publication Critical patent/JP2023534916A/ja
Publication of JPWO2022006283A5 publication Critical patent/JPWO2022006283A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2022581408A 2020-06-30 2021-06-30 視神経脊髄炎スペクトラム障害を治療する方法 Pending JP2023534916A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063046133P 2020-06-30 2020-06-30
US63/046,133 2020-06-30
US202063052093P 2020-07-15 2020-07-15
US63/052,093 2020-07-15
US202063071092P 2020-08-27 2020-08-27
US63/071,092 2020-08-27
PCT/US2021/039911 WO2022006283A2 (en) 2020-06-30 2021-06-30 Methods of treating neuromyelitis optica spectrum disorder

Publications (2)

Publication Number Publication Date
JP2023534916A true JP2023534916A (ja) 2023-08-15
JPWO2022006283A5 JPWO2022006283A5 (enExample) 2024-07-09

Family

ID=79321915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022581408A Pending JP2023534916A (ja) 2020-06-30 2021-06-30 視神経脊髄炎スペクトラム障害を治療する方法

Country Status (11)

Country Link
US (1) US20230406928A1 (enExample)
EP (1) EP4172211A4 (enExample)
JP (1) JP2023534916A (enExample)
KR (1) KR20230030642A (enExample)
CN (1) CN116234571A (enExample)
AU (1) AU2021299307A1 (enExample)
BR (1) BR112022026747A2 (enExample)
CA (1) CA3178954A1 (enExample)
IL (1) IL299381A (enExample)
MX (1) MX2022016236A (enExample)
WO (1) WO2022006283A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230097118A (ko) * 2020-10-29 2023-06-30 비엘라 바이오, 인크. 자가면역 질환을 치료하기 위한 항-cd19 항체의 사용
CN117797245A (zh) * 2023-12-29 2024-04-02 广州赛莱拉干细胞科技股份有限公司 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021020924A2 (pt) * 2019-04-24 2022-04-19 Viela Bio Inc Uso de um anticorpo anti-cd19 para tratar doença autoimune
KR20230097118A (ko) * 2020-10-29 2023-06-30 비엘라 바이오, 인크. 자가면역 질환을 치료하기 위한 항-cd19 항체의 사용

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, vol. 7, no. 6, JPN6025029319, 2020, pages 992 - 1001, ISSN: 0005644205 *
LANCET, vol. 394, JPN6025029316, 2019, pages 1352 - 1363, ISSN: 0005644202 *
NEUROLOGY, vol. Vol.94 (15_supplement), JPN6025029317, 14 April 2020 (2020-04-14), ISSN: 0005644203 *
PLOS ONE, vol. Vol.6, Issue 8, e23489, JPN6025029318, August 2011 (2011-08-01), ISSN: 0005644204 *

Also Published As

Publication number Publication date
WO2022006283A2 (en) 2022-01-06
AU2021299307A1 (en) 2022-12-22
US20230406928A1 (en) 2023-12-21
MX2022016236A (es) 2023-03-29
EP4172211A2 (en) 2023-05-03
WO2022006283A3 (en) 2022-02-03
EP4172211A4 (en) 2024-07-10
CA3178954A1 (en) 2022-01-06
IL299381A (en) 2023-02-01
KR20230030642A (ko) 2023-03-06
CN116234571A (zh) 2023-06-06
BR112022026747A2 (pt) 2023-01-24

Similar Documents

Publication Publication Date Title
CN115175701A (zh) 用于治疗甲状腺眼病的方法
Menon et al. Management of optic neuritis
Gallo et al. Overview of the management of relapsing− remitting multiple sclerosis and practical recommendations
US20230406928A1 (en) Methods of treating neuromyelitis optica spectrum disorder
KR20220004113A (ko) 자가면역 질환을 치료하기 위한 항-cd19 항체의 용도
US20230287114A1 (en) Use of an anti-cd19 antibody to treat autoimmune disease
JP2023548005A (ja) 抗トランスサイレチン抗体およびその使用方法
Kupersmith et al. Magnetic resonance angiography and clinical evaluation of third nerve palsies and posterior communicating artery aneurysms
Akaishi et al. Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD
EP4426349A2 (en) Methods for treating alzheimer's disease
Fox et al. Thyroid eye disease: Management, Advances and Future Opportunities
HK40087593A (zh) 治疗视神经脊髓炎谱系障碍的方法
Kamijo et al. Successful maintenance therapy with intravenous immunoglobulin to reduce relapse attacks and steroid dose in a patient with refractory myelin oligodendrocyte glycoprotein antibody-positive optic neuritis
TW202317181A (zh) 治療視神經脊髓炎譜系障礙之方法
Shi et al. Clinical image and pathology of hypertrophic cranial pachymeningitis
Chan Optic neuritis
Chen et al. Optic Neuritis
Bhari et al. OPTIC NEURITIS AND MULTIPLE SCLEROSIS
Chen et al. Optic Neuritis
Grzybowski et al. Treatment of optic neuritis
Kanikannan et al. A characteristic analysis of longitudinally extensive transverse myelitis in South Indian population: A cohort study
Maharrey Case Report: Successful Visual Recovery in Neuromyelitis Optica Spectrum Disorder
Marrie et al. Interferons in secondary progressive multiple sclerosis
Penas et al. Chronicity and recurrence as prognostic factors in central serous chorioretinopathy after half-dose photodynamic therapy
JPWO2022094334A5 (enExample)

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251216